Scarica l'app Stockscreener
9.94
3.01%
0.29
Dopo l'orario di chiusura:
11.00
1.06
+10.66%
Precedente Chiudi:
$9.65
Aprire:
$10
Volume 24 ore:
110.85K
Relative Volume:
2.32
Capitalizzazione di mercato:
$162.40M
Reddito:
-
Utile/perdita netta:
$-33.82M
Rapporto P/E:
-0.3884
EPS:
-25.5891
Flusso di cassa netto:
$-66.04M
1 W Prestazione:
+9.59%
1M Prestazione:
+10.44%
6M Prestazione:
+21.66%
1 anno Prestazione:
+131.70%
Intervallo 1D:
$9.67
$10.05
Intervallo di 1 settimana:
$8.51
$10.05
Portata 52W:
$3.70
$10.75
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Nome
Elicio Therapeutics Inc
Settore
Industria
Telefono
(857) 209-0050
Indirizzo
451 D STREET, 5TH FLOOR, BOSTON
Confronta ELTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.94 | 157.66M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Borsa (ELTX) Ultime notizie
Elicio Therapeutics Inc. Chart Enters High Volatility ZoneJuly 2025 Rallies & Weekly Return Optimization Alerts - newsyoung.net
How hedge fund analytics apply to Elicio Therapeutics Inc. stockJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Signal strength of Elicio Therapeutics Inc. stock in tech scannersProduct Launch & Accurate Buy Signal Alerts - Newser
Is Elicio Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisJuly 2025 Price Swings & Accurate Intraday Trading Signals - Newser
Evaluating Elicio Therapeutics Inc. with trendline analysis2025 Momentum Check & Community Supported Trade Ideas - Newser
Risk vs reward if holding onto Elicio Therapeutics Inc.2025 Dividend Review & Growth-Oriented Investment Plans - Newser
Elicio Therapeutics Inc. stock outlook for YEARWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - Newser
Market reaction to Elicio Therapeutics Inc.’s recent newsOptions Play & Weekly Chart Analysis and Guides - Newser
Applying chart zones and confluence areas to Elicio Therapeutics Inc.July 2025 Price Swings & Consistent Growth Equity Picks - Newser
Why Elicio Therapeutics Inc. is moving today2025 Trade Ideas & Fast Entry Momentum Trade Alerts - Newser
Key External Factors That Drive Elicio Therapeutics Inc. Stock Price MovementsQuarterly Risk Review & Weekly Top Gainers Alerts - Newser
Elicio’s peptide cancer vaccine shows survival benefit in Phase I trial - Yahoo Finance
Is it too late to sell Elicio Therapeutics Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - Newser
Can technical indicators confirm Elicio Therapeutics Inc.’s reversal2025 Retail Activity & Long-Term Growth Stock Strategies - Newser
News impact scoring models applied to Elicio Therapeutics Inc.Profitable Trading Blueprint with Entry Zones - Newser
What to expect from Elicio Therapeutics Inc. in the next 30 daysFree Opportunity Map for Daily Stock Trading - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc.2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Visual trend scoring systems applied to Elicio Therapeutics Inc. [2025 Momentum Check]Technical Pattern Recognition Alerts - Newser
Is Elicio Therapeutics Inc. Stock a Good Fit for Conservative InvestorsPortfolio Building Plan and Summary Guide - Newser
Elicio Therapeutics Announces Publication of ELI-002 - GlobeNewswire
Can trapped investors hope for a rebound in Elicio Therapeutics Inc.Free Portfolio Diversification Stock Ideas - Newser
Amplify Energy Corp. shares rise 4.69% intraday after Elicio Therapeutics published positive clinical trial results for ELI-002. - AInvest
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
BostonGene's AI-Powered Oncology Platform Achieves Landmark Validation in Study - AInvest
Elicio Therapeutics Publishes Promising Phase 1 Study Data - TipRanks
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - GlobeNewswire Inc.
Elicio Therapeutics Reports Q2 2025 Financial Results: $10.6M Net Loss, $22.3M Raised in Financing Activities - AInvest
Chart based analysis of Elicio Therapeutics Inc. trendsFree Risk Controlled Short Term Trade Plans - Newser
Analyzing Elicio Therapeutics Inc. with multi timeframe chartsTrading Volume Anomaly Summary and Insight - Newser
What does recent volatility data suggest for Elicio Therapeutics Inc.Risk Balanced Picks for Safer Trading - Newser
What makes Elicio Therapeutics Inc. stock price move sharplyNext Day Momentum Stock Forecasting Report - Newser
Elicio Therapeutics Reports Q2 2025 Financial Results - TipRanks
Elicio Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
What recovery options are there for Elicio Therapeutics Inc.Free Market Entry and Exit Point Tips - Newser
Analyzing recovery setups for Elicio Therapeutics Inc. investorsFree Real Market Momentum Signal Generator - Newser
Is Elicio Therapeutics Inc. meeting your algorithmic filter criteriaFree Triple Digit Return Stock Predictions - Newser
ringostarr> 2025> Is There Enough Volume to Lift Elicio Therapeutics Inc.Free High-Accuracy Stock Picks - beatles.ru
Is Elicio Therapeutics Inc. stock risky to hold nowFlash Gain Trade Picks - mustnews.co.kr
Elicio Therapeutics Inc. Reaches Critical Trendline SupportBuy Signal Based on Chart Analysis Confirmed - metal.it
Using Bollinger Bands to evaluate Elicio Therapeutics Inc.High Yield Watchlist with Filtered Picks - Newser
Elicio (ELTX) Q2 Loss Beats Estimates - AOL.com
Elicio Therapeutics Q2 Results: Net Loss Beats Estimates, R&D Spending Down - AInvest
Predicting Elicio Therapeutics Inc. trend using moving averagesTechnical Trend Forecast for Investors - Newser
Elicio Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Elicio Therapeutics (ELTX): Clinical Progress Outpaces Financial Losses - AInvest
Elicio Therapeutics Reports Q2 GAAP EPS of -$0.66, Expects Cash to Support Operations into Q1 2026 - AInvest
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX) - The Globe and Mail
Elicio Therapeutics Inc Azioni (ELTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):